Western blot analysis of human and mouse cell lines using anti-human NLRP1/NALP1 antibody (AL176) (Prod. No. AG-25B-0005).Method: Total protein extracts (20microg) from various human (293-T, Jurkat, Raj, Ramos, BJAB, THP-1, U937, K56
anti-NLRP1/NALP1 (human), pAb (AL176)
AG-25B-0005
ApplicationsWestern Blot, ImmunoHistoChemistry
Product group Antibodies
ReactivityHuman
TargetNLRP1
Overview
- SupplierAdipoGen Life Sciences
- Product Nameanti-NLRP1/NALP1 (human), pAb (AL176)
- Delivery Days Customer10
- Antibody SpecificityRecognizes human NLRP1/NALP1. Does not cross-react with mouse NLRP1/NALP1.
- ApplicationsWestern Blot, ImmunoHistoChemistry
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- FormulationLiquid
- Gene ID22861
- Target nameNLRP1
- Target descriptionNLR family pyrin domain containing 1
- Target synonymsAIADK; CARD7; caspase recruitment domain protein 7; caspase recruitment domain-containing protein 7; CIDED; CLR17.1; death effector filament-forming Ced-4-like apoptosis protein; DEFCAP; DEFCAP-L/S; JRRP; MSPC; NAC; NACHT, leucine rich repeat and PYD (pyrin domain) containing 1; NACHT, leucine rich repeat and PYD containing 1; NACHT, LRR and PYD containing protein 1; NACHT, LRR and PYD domains-containing protein 1; NALP1; nucleotide-binding domain and caspase recruitment domain; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 1; PP1044; SLEV1; VAMAS1
- HostRabbit
- Protein IDQ9C000
- Protein NameNACHT, LRR and PYD domains-containing protein 1
- Scientific DescriptionNALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus. - Polyclonal Antibody. Recognizes human NLRP1/NALP1. Does not cross-react with mouse NLRP1/NALP1. Source: Rabbit. Applications: WB. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
- ReactivityHuman
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352203